BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29135583)

  • 1. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.
    Lodi S; Günthard HF; Dunn D; Garcia F; Logan R; Jose S; Bucher HC; Scherrer AU; Schneider MP; Egger M; Glass TR; Reiss P; van Sighem A; Boender TS; Phillips AN; Porter K; Hawkins D; Moreno S; Monge S; Paraskevis D; Simeon M; Vourli G; Sabin C; Hernán MA;
    AIDS; 2018 Jan; 32(3):327-335. PubMed ID: 29135583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
    Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
    Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
    Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
    AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
    Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
    HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal analysis of sociodemographic, clinical and therapeutic factors of HIV-infected individuals in Kinshasa at antiretroviral therapy initiation during 2006-2017.
    Ngongo NM; Darcis G; Nanituna HS; Mambimbi MM; Maes N; Mashi ML; Bepouka Izizag B; Moutschen M; Lepira Bompeka F
    PLoS One; 2021; 16(11):e0259073. PubMed ID: 34739506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study.
    Chammartin F; Lodi S; Logan R; Ryom L; Mocroft A; Kirk O; d'Arminio Monforte A; Reiss P; Phillips A; El-Sadr W; Hatleberg CI; Pradier C; Bonnet F; Law M; De Wit S; Sabin C; Lundgren JD; Bucher HC;
    Ann Intern Med; 2021 Jun; 174(6):768-776. PubMed ID: 33721519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.
    Iwuji CC; Orne-Gliemann J; Tanser F; Boyer S; Lessells RJ; Lert F; Imrie J; Bärnighausen T; Rekacewicz C; Bazin B; Newell ML; Dabis F;
    Trials; 2013 Jul; 14():230. PubMed ID: 23880306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
    Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
    AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
    Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
    Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.
    Caniglia EC; Cain LE; Sabin CA; Robins JM; Logan R; Abgrall S; Mugavero MJ; Hernández-Díaz S; Meyer L; Seng R; Drozd DR; Seage GR; Bonnet F; Dabis F; Moore RD; Reiss P; van Sighem A; Mathews WC; Del Amo J; Moreno S; Deeks SG; Muga R; Boswell SL; Ferrer E; Eron JJ; Napravnik S; Jose S; Phillips A; Justice AC; Tate JP; Gill J; Pacheco A; Veloso VG; Bucher HC; Egger M; Furrer H; Porter K; Touloumi G; Crane H; Miro JM; Sterne JA; Costagliola D; Saag M; Hernán MA; ;
    Lancet HIV; 2017 Jun; 4(6):e251-e259. PubMed ID: 28411091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
    Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
    Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data.
    Kufa T; Shubber Z; MacLeod W; Takuva S; Carmona S; Bor J; Gorgens M; Pillay Y; Puren A; Eaton JW; Fraser-Hurt N
    PLoS One; 2019; 14(5):e0217742. PubMed ID: 31150489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
    Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
    AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal immune recovery and associated factors among people living with HIV/AIDS on second-line antiretroviral therapy in central China: A retrospective cohort study.
    Zhu K; Xu Q; Ma Y; Li P; Jia H; Jiang Q; Wang Y; Wu Z; Wang D; Guo H; Jin Y
    J Med Virol; 2022 Oct; 94(10):4975-4982. PubMed ID: 35710693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.
    Jose S; Quinn K; Hill T; Leen C; Walsh J; Hay P; Fisher M; Post F; Nelson M; Gompels M; Johnson M; Chadwick D; Gilson R; Sabin C; Fidler S;
    AIDS; 2014 Jun; 28(9):1333-9. PubMed ID: 24583670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052.
    Palumbo PJ; Fogel JM; Hudelson SE; Wilson EA; Hart S; Hovind L; Piwowar-Manning E; Wallis C; Papathanasopoulos MA; Morgado MG; Saravanan S; Tripathy S; Eron JJ; Gallant JE; McCauley M; Gamble T; Hosseinipour MC; Kumarasamy N; Hakim JG; Pilotto JH; Kumwenda J; Akelo V; Godbole SV; Santos BR; Grinsztejn B; Panchia R; Chariyalertsak S; Makhema J; Badal-Faesen S; Chen YQ; Cohen MS; Eshleman SH
    J Acquir Immune Defic Syndr; 2018 Apr; 77(5):484-491. PubMed ID: 29293156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa.
    Balestre E; Eholié SP; Lokossue A; Sow PS; Charurat M; Minga A; Drabo J; Dabis F; Ekouevi DK; Thiébaut R;
    AIDS; 2012 May; 26(8):951-7. PubMed ID: 22382142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on ART initiation of point-of-care CD4 testing at HIV diagnosis among HIV-positive youth in Khayelitsha, South Africa.
    Patten GE; Wilkinson L; Conradie K; Isaakidis P; Harries AD; Edginton ME; De Azevedo V; van Cutsem G
    J Int AIDS Soc; 2013 Jul; 16(1):18518. PubMed ID: 23830642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
    Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
    HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.